Search

Sarepta Therapeutics Inc

Suletud

SektorTervishoid

19.97 -3.39

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

19.59

Max

20.11

Põhinäitajad

By Trading Economics

Sissetulek

-4.9M

326M

Müük

-330M

401M

P/E

Sektori keskmine

42.919

56.432

Aktsiakasum

0.42

Kasumimarginaal

81.263

Töötajad

835

EBITDA

-345M

30M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+10.82% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

2. nov 2026

Turustatistika

By TradingEconomics

Turukapital

533M

2.2B

Eelmine avamishind

23.36

Eelmine sulgemishind

19.97

Uudiste sentiment

By Acuity

40%

60%

70 / 339 Pingereas Healthcare

Sarepta Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. sept 2026, 19:51 UTC

Sarepta Therapeutics Inc shares fell sharply, continuing a significant decline since Thursday and trading well below its 20-day moving average.

17. sept 2026, 20:02 UTC

Sarepta Therapeutics Inc shares are sharply higher, showing notable volatility and remaining well above the 20-day moving average since Wednesday's close.

16. sept 2026, 23:06 UTC

Sarepta Therapeutics Inc. is trading modestly higher in after-market hours following a notable early spike, despite closing lower in three consecutive sessions.

14. sept 2026, 20:07 UTC

Sarepta Therapeutics shares are higher, reflecting broader market strength despite pulling back from an earlier session peak. No specific news was identified for the movement.

12. sept 2026, 00:01 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading, following a decline earlier in the session amid broader inflation concerns ahead of a Federal Reserve meeting.

11. sept 2026, 23:31 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours with no specific news to explain the decline amid broader market speculation on Federal Reserve rate hikes.

10. sept 2026, 20:03 UTC

Sarepta Therapeutics Inc shares are lower today, continuing a decline since Wednesday. No specific news was identified to explain the drop.

9. sept 2026, 23:21 UTC

Sarepta Therapeutics shares are lower in after-market hours, following a broader market trend amid rising U.S. Treasury yields impacting borrowing costs.

8. sept 2026, 23:21 UTC

Social Media

Sarepta Therapeutics is higher in after-market trading amid social media interest in its $2.1 billion market cap and revenue projections for fiscal year 2026.

4. sept 2026, 23:25 UTC

Sarepta Therapeutics Inc. shares declined after-market, reflecting unusual weakness since Friday's close, despite remaining above the 20-day moving average.

3. sept 2026, 23:36 UTC

Sarepta Therapeutics Inc. shares traded roughly flat after market hours, while major indices gained amid easing interest rate concerns.

2. sept 2026, 20:02 UTC

Social Media

Sarepta Therapeutics shares are higher as investor interest grows ahead of clinical data for treatments targeting muscular dystrophy, despite a pullback from session highs.

1. sept 2026, 20:09 UTC

Sarepta Therapeutics Inc shares are higher today, supported by gains in the Biotechnology sub-sector. The stock remains above its 20-day moving average.

31. aug 2026, 20:07 UTC

Sarepta Therapeutics shares are higher amid broader market concerns over inflation, with no specific company news identified to explain the movement.

28. aug 2026, 19:51 UTC

News

Sarepta Therapeutics reported a 34% revenue decline to $401.3 million for Q2 2026, as execution risks weigh on shares during the current session.

27. aug 2026, 23:02 UTC

Sarepta Therapeutics shares declined in after-market trading amid a broader market pullback, despite earlier gains during the session. No specific news was identified.

26. aug 2026, 20:08 UTC

Sarepta Therapeutics Inc shares are higher today amid broader market gains, despite no specific company news identified. Recent inflation data may be influencing market trends.

25. aug 2026, 19:26 UTC

Sarepta Therapeutics Inc. shares are higher today amid notable volatility, despite no specific news to explain the movement. Broader market conditions support higher valuations.

24. aug 2026, 20:06 UTC

News

Sarepta Therapeutics shares decline amid investigation into potential fiduciary breaches and safety concerns regarding its gene therapy, Elevidys.

21. aug 2026, 19:26 UTC

Sarepta Therapeutics Inc is trading lower today, with no specific news identified for the decline. Broader market trends show a rebound in U.S. stocks.

20. aug 2026, 23:56 UTC

Sarepta Therapeutics Inc. shares traded roughly flat in after-market hours, remaining above their 20-day moving average and near the upper end of their one-month range.

19. aug 2026, 23:11 UTC

Sarepta Therapeutics shares are lower in after-market hours amid a broader decline in the Biotechnology sub-sector, showing unusual volatility during the session.

18. aug 2026, 23:11 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, retracing gains amid broader market weakness linked to rising sovereign bond yields and inflation concerns.

17. aug 2026, 19:36 UTC

Sarepta Therapeutics Inc shares are higher, continuing their advance since Friday's close and trading above the 20-day moving average. No specific news was identified.

14. aug 2026, 19:36 UTC

Sarepta Therapeutics shares are lower today amid broader market sentiment following a reported decline in retail sales for July. No specific company news was identified.

13. aug 2026, 19:36 UTC

Sarepta Therapeutics shares are trading roughly flat, with no specific news identified. The price remains significantly above the 20-day moving average.

12. aug 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market hours, continuing a decline since Wednesday's close, with no specific news identified to explain the drop.

11. aug 2026, 23:51 UTC

Sarepta Therapeutics Inc shares are lower in after-market trading. No specific news was identified to explain the movement amid broader market focus on inflation data.

10. aug 2026, 23:52 UTC

Sarepta Therapeutics shares are lower in after-market hours, with no specific news identified for the decline amid broader market sentiment influenced by labor report data.

7. aug 2026, 19:36 UTC

News

Sarepta Therapeutics reports Q2 2026 revenue of $401.3 million, down from $611.1 million a year earlier, with shares trading lower during the session.

Võrdlus sarnastega

Hinnamuutus

Sarepta Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

10.82% tõus

12 kuu keskmine prognoos

Keskmine 22.286 USD  10.82%

Kõrge 38 USD

Madal 5 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Sarepta Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

16 ratings

4

Osta

8

Hoia

4

Müü

Sentiment

By Acuity

70 / 339 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.